Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells

Leukemia

Volumn 13, Issue 4, 1999, Pages 568-577

  Engel, H ^a,c   Drach, J ^a   Keyhani, A ^a   Jiang, S ^a   Van, N T ^a   Kimmel, M ^b   Sanchez Williams, G ^a   Goodacre, A ^a   Andreeff, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Rice University   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute myelogenous leukemia; Cytogenetics; Fluorescence activated cell sorting; Fluorescence in situ hybridization; Minimal residual disease; Myelodysplastic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 3; METHOTREXATE; MITOXANTRONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CELL PROLIFERATION; CHROMOSOME 17; CHROMOSOME 18; CHROMOSOME 8; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLONE; CYTOGENETICS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MONOSOMY; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; PARTIAL TRISOMY 10; PARTIAL TRISOMY 9; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; TRISOMY 8;

EID: 0032916077     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401359     Document Type: Article

References (59)

1. Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 1992; 6: 500-506.
2. Mayer RJ, Acute leukemias in adults: an overview of recent strategies. J Cancer Res Clin Oncol 1990; 116: 94-96.
3. Rees JKH. Aspects of treatment of acute myeloid leukemia in adults. Curr Opin Oncol 1993; 5: 53-70.
4. Estey EH, Thall P, Andreeff M, Beran M, Kantarjian HM, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierce S, Freireich EJ, Deisseroth AB, Keating MJ. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12: 671-678.
5. Van der Leiv N, Poddighe P, Hopman A, De Witte T. Cytogenetic studies of progenitor cell origin by in situ hybridization (ISH) in patients with acute myeloid leukemia (AML) (Meeting abstract). Exp Hematol 1991; 99: 530.
6. Hagenbeek A. Minimal residual disease in leukemia: state of the art. Leukemia 1992; 6: 12-16.
7. Andreeff M, Redner A, Thongprasert S, Eagle B, Steinherz P, Miller D, Melamed MR. Multiparameter flow cytometry for ploidy determination, proliferation and differentiation in acute leukemia: treatment effects and prognostic value. In: Buechner T (ed). Tumor Aneuploidy. Springer-Verlag: Berlin, 1985, pp 81-105.
8. Estey E, Thall P, Kantarjian HM, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (CM-CSF) before and during continuous-infusion high-dose Ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246-2253.
9. Woermann B. Implications of detection of minimal residual disease. Curr Opin Oncol 1993; 5: 3-12.
10. Gerhartz HH, Schmetzer H. Detection of minimal residual disease in acute myeloid leukemia. Leukemia 1990; 4: 508-516.
11. Baurmann H, Cherif D, Berger R. Interphase cytogenetics by fluorescent in situ hybridization (FISH) for characterization of monosomy-7-associated myeloid disorders. Leukemia 1993; 7: 384-391.
12. Bernasconi P, Alessandrino EP, Boni M, Bonfichi M, Morra E, Lazzarino M, Campagnoli C, Astori C. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution and survival. Am J Hematol 1994; 46: 270-277.
13. Casey G, Rudzki Z, Roberts M, Hutchins C, Juttner C. N-ras mutation in acute myeloid leukemia: incidence, prognostic significance and value as a marker of minimal residual disease. Pathology 1993; 25: 57-62.
14. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB. Treatment of poor-prognosis newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990; 75: 1766-1769.
15. Bennett JM. Detection of relapse in acute leukemia: should we discontinue routine bone marrow surveillance? Leukemia 1992; 6: 1099-1100.
16. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative high sensitivity fluorescence hybridization. Proc Natl Acad Sci USA 1986; 83: 2934-2938.
17. Anastasi J, Le Beau MM, Vardiman JW, Westbrook CA. Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells using in situ hybridization with a chromosome-specific probe. Am J Pathol 1990; 136: 131-139.
18. Poddighe PJ, Moesker O, Smeets D, Awwad BH, Ramaekers FCS, Hopman AHN. Interphase cytogenetics of hematological cancer: comparison of classical karyotyping and in situ hybridization using a panel of eleven chromosome specific DNA probes. Cancer Res 1991; 51: 1959-1967.
19. Stass SA, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood 1984; 64: 701-706.
20. Thomas X, Campos L, Archimbaud E. Surface marker expression in acute myeloid leukemia at first relapse. Br J Haematol 1992; 81: 40-44.
21. Garson OM, Hagemejer A, Sakurari M. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genet Cytogenet 1989; 40: 197-202.
22. Estrov Z, Grunberger T, Dulbe ID, Wang Y-P, Freedman MH. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. New Engl J Med 1986; 315: 538-542.
23. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990; 76: 163-171.
24. Campara D. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results. Int J Clin Lab Res 1994; 24: 1-7.
25. + malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993; 7: 853-858.
26. Campana D, Freitas RO, Coustan-Smith E. Detection of minimal residual disease with immunologic methods: technical developments and clinical implications. Leuk Lymphoma 1994; 13: 31-34.
27. Campana D. Detection of minimal residual disease in leukemia and lymphoma. Rec Adv Hematol 1993; 7: 21-34.
28. Terstappen LWMM, Safford M, Koenemann S, Loken MR, Zurlutter K, Buechner T, Hiddemann W, Wörmann B. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1991; 5: 70-80.
29. Campana D. Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 1994; 18: 68-74.
30. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992; 13: 893-901.
31. van Dongen JM, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6: 47-59.
32. Potter MN, Cross NC, van Dongen JJ, Saglio G, Oakhill A, Bartram CR, Goldman JM. Molecular evidence of minimal residual disease after treatment for leukemia and lymphoma: an updated meeting report and review. Leukemia 1993; 7: 1302-1314.
33. Vogler WR. Strategies in the treatment of acute myelogenous leukemia. Leukemia Res 1992; 16: 1143-1153.
34. Chang KS, Fan YH, Stass SH, Estey EH, Wang G, Trujillo JM, Erickson P, Drabkin H. The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: targets for the detection of minimal residual disease by polymerase chain reaction. Blood 1992; 79: 554-558.
35. Biondi A, Rambaldi A, Pandolfi PP. Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80: 492-497.
36. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Pett MC, McIondi G. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340: 1437-1438.
37. van de Locht LT, Smetsers TF, Wittebol S, Raymakers RA, Mensik EJ. Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukemia. Leukemia 1994; 8: 1780-1784.
38. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kahls P, Linkesch W, Schwarzinger I, Mitterbauer G, Purtscher B. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994; 8: 735-739.
39. Anastasi J, Feng I, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 1993; 81: 1580-1585.
40. Zhao L, Chang KS, Estey EH, Hayes K, Deisseroth AB, Liang JC. Detection of residual leukemic cells in patients with acute promyelocytic leukemia by fluorescence in situ hybridization: potential for predicting relapse. Blood 1995; 85: 495-499.
41. El-Rifai W, Ruutu T, Elonen E, Volin L, Knuutila S. Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. Blood 1997; 89: 3330-3334.
42. Andreeff M, Drach J, Tafuri A. Interleukin-3 before and during idarubicin/Ara-C in acute myeloblastic leukemia. Blood 1992; 80: 111a.
43. Grimwade D, Walker H, Harrison C, Oliver F, Wheatley K, Harrison G, Gray R, Hann I, Stevens R, Rees J, Goldstone A, Burnett A. Impact of diagnostic cytogenetics on outcome in AML: analysis of 1613 patients entered into the UK MRC AML 10 trial. Blood 1996; 88: 634a.
44. Wheatly K, Burnett AK, Goldstone AH, Hann IM, Stevens RF, Rees JKH, Gray RG. Factors relating to the achievement of complete remission (CR) in younger patients with acute myeloid leukaemia (AML) in the United Kingdom Medical Research Council (MRC) AML 10 trial. Blood 1996; 88: 214a.
45. Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AK. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th trial (MRC 10). Blood 1997; 89: 2311-2318.
46. Zhang T, Hillion J, Tong JH, Cao Q, Chen SJ, Berger R, Chen Z. AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21) Leukemia 1994; 8: 729-734.
47. Maruyama F, Stass SA, Estey EH, Cork A, Hirano M, Ino T, Freireich EJ, Yang P, Chang KS. Detection of AML1/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia. Leukemia 1994; 8: 40-45.
48. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New Engl J Med 1997; 336: 317-323.
49. Tobal K, Liu Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTC8 transcripts in AML-M2 with t(8;21 ). Blood 1996; 88: 3704-3709.
50. Babusikova O, Mesarosova A, Konikova M, Kusenda J, Glasova M, Klobusicka M. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease. Neoplasma 1993; 40: 275-281.
51. Reading CL, Estey EJ, Huh YO, Claxton DF, Sanchez G, Terstappen LWMM, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083-3090.
52. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90: 2465-2470.
53. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 1994; 91: 3497-3504.
54. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen THM, van Kalken CK, Stovak ML, de Vries EGE, van der Valk P, Meijer CJLM, Pinedo HM. Overexpression of a M, 110 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-1479.
55. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Berstein ID, Dow LW, Najfeld V, Veith R. Clonal development, stem cell differentiation and the nature of clinical remission in acute nonlymphocytic leukemia; studies of patients heterozygous for glucose-6-phoshate dehydrogenase. New Engl J Med 1987; 317: 468-473.
56. Fialkow PJ, Janssen JWG, Bartram CR. Clonal remissions in acute nonlymphocytic leukemia: evidence for multistep pathogenesis of the malignancy. Blood 1991; 77: 1415-1417.
57. Paskulin GA, Philips G, Morgan R, Sandberg A, Richkind K, Borovik C, McGavran L, Rabinovich N, Dietz-Band J, Erickson P, Drabkin H, Varella-Garcia M. Pre-clinical evaluation of probes to detect t(8;21) AML minimal residual disease by fluorescence in situ hybridization. Genes Chromos Cancer 1998; 21: 144-151.
58. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 21: 159-166.
59. Engel H, Goodacre A, Keyhani A, Jiang S, Van NT, Kimmel M, Sanchez-Williams G, Andreeff M. Minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. Br J Haematol 1997; 99: 64-75.